Trending Now
2022 is Turning into the Year of the Energy Stock Boom...
Unless you’ve been living under a rock for the past 6 weeks, you are painfully aware of recent events in eastern Europe....
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Oragenics Inc. (NYSEAMERICAN:OGEN) Receives Positive Feedback From The FDA On Development...
Oragenics Inc. (NYSEAMERICAN:OGEN) Has announced that it has received feedback from the FDA to its Type B Pre-IND Meeting Request. The response is in...
MAKE IT MODERN
LATEST REVIEWS
IPO’s and Market on Thanks Giving Day
This will be a short a sweet one today as this is historically a very low volume day in the market.
MAKE IT MODERN
PERFORMANCE TRAINING
Peloton’s ($PTON) Rocky Fiscal Fourth Quarter: A Dive into Subscriber Drop and Product Recall
Shares of Peloton (NASDAQ:PTON), the renowned fitness equipment and media company, plummeted about 23% in early trading on Wednesday. The dip...
IVERIC bio Inc. (NASDAQ:ISEE) Says the Results From its GATHER1 Phase 3 Clinical Trial...
IVERIC bio Inc (NASDAQ:ISEE) has had consistent success in the development of treatments addressing age-related and retinal diseases. Zimura® (avacincaptad pegol) is one of...
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Holds Cash Balance Of $68 Million
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) reported an increase in R&D expenses to $3.4 million and posted a net loss of $5.8 million. The company...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) Receives IND Clearance For TNX-2100 and Partners To...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced that the FDA had cleared its IND application to commence first-in-human clinical trials for TNX-2100, a skin...
Aditxt Inc (NASDAQ: ADTX) Announces Promising Toxicology Results Confirming ADI-100’s Safety Profile In Human...
Aditxt Inc (NASDAQ: ADTX) has announced that its therapeutic project Adimmune has finalized a toxicology study showing ADI-100's safety profile. ADI-100 is Aditxt’s immunotherapeutic...
MAKE IT MODERN
